Literature DB >> 7560017

HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barré syndrome.

A Chiba1, S Kusunoki, S Kuwata, T Juji, Y Shibata, I Kanazawa.   

Abstract

We investigated serological human leukocyte antigen (HLA) types in patients with histories of Miller Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS) with ophthalmoplegia, in whom serum anti-GQ1b IgG antibody was present during the acute phase. We examined class I antigens (A, B and C) in 32 patients and class II antigens (DR and DQ) in 30, but found no association. We conclude that particular serologically defined HLA types are not preferred for the immunoresponse of anti-GQ1b IgG antibody in MFS and GBS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560017     DOI: 10.1016/0165-5728(95)00079-h

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

Review 1.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

Review 2.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

Review 3.  Campylobacter species and Guillain-Barré syndrome.

Authors:  I Nachamkin; B M Allos; T Ho
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

4.  Ataxia, ophthalmoplegia, and areflexia: what would you think?

Authors:  N Karsan; P Fletcher; I Bodi; B K Macdonald
Journal:  Case Rep Neurol Med       Date:  2012-06-27

5.  Mother and son cases of Bickerstaff's brainstem encephalitis and fisher syndrome with serum anti-GQ1b IgG antibodies: a case report.

Authors:  Hirokazu Natsui; Makoto Takahashi; Kentaro Nanatsue; Sakiko Itaya; Keisuke Abe; Akira Inaba; Satoshi Orimo
Journal:  BMC Neurol       Date:  2021-03-20       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.